 NEW YORK, May 17, 2021 PRNewswire -- Seelos Therapeutics, Inc. Nasdaq: SEEL, a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system CNS disorders and rare diseases, today announced positive data from Part 1, the open-label cohort, of its potentially registrational Proof-of-Concept study of SLS-002 intranasal racemic ketamine demonstrating a significant treatment effect and a well-tolerated safety profile for Acute Suicidal Ideation and Behavior ASIB in patients with Major Depressive Disorder MDD. Rapid and clinically meaningful efficacy both as an anti-depressive and anti-suicidal therapeutic after a single dose This study enrolled 17 subjects diagnosed with MDD requiring psychiatric hospitalization due to significant risk of suicide with a baseline score of 28 points on the Montgomery-Åsberg Depression Rating Scale MADRS, a score of 5 or 6 on MADRS Item-10, a score of 15 points on the Sheehan-Suicidality Tracking Scale S-STS total score and a history of previous suicide attempts, as confirmed on the Columbia Suicide Severity Rating Scale C-SSRS with a history of at least one actual attempt, or if the attempt was interrupted or aborted, is judged to have been serious in intent. 